ROR1 and neoplasm: Overall, tMUC, αvβ3, TEM8, and ROR1 have been successfully targeted by CAR T cells, which will hopefully stimulate intense research into other tumor-specific or tumor-associated antigens that can be targeted by immunotherapy (Table 1).